奥沙利铂联合S-1治疗晚期老年胃癌的疗效及安全性分析

Analysis of Efficacy and Safety in Elderly Patients with Advanced and Metastatic Gastric Cancer Treated by Oxaliplatin and S-1

目的:总结单药S-1及S-1联合奥沙利铂(SOX)治疗老年晚期胃癌的疗效及安全性。方法:将2010年1月至2013年12月我院收治的符合研究条件的老年晚期胃癌患者74例根据化疗方法分为S-1组(n=48)和SOX组(n=26),比较两组的疗效及安全性。结果:S-1组的治疗反应率、中位OS期、中位无进展生存(PFS)时间均明显短于SOX组(27.1%vs 42.3%、9.2月vs 15.3月、4.1月vs 7.3月),P均<0.05;S-1组的白细胞降低、中性粒细胞降低、食欲下降、恶心、呕吐、感觉神经病的发生率均明显高于SOX组(23.1%vs 4.2%、26.9%vs 6.3%、26.9%vs 16.7%、23.1%vs 4.2%、15.4%vs 0.0%、15.4%vs 0.0%),P均<0.05。结论 :与S-1方案比较,SOX方案可提高老年晚期胃癌患者OS,且耐受性良好。

Objective：To summarize the efficacy and safety of S-1 alone or S-1 plus oxaliplatin （SOX） for elderly patients with advanced gastric cancer. Methods 74 elderly patients with advanced gastric cancer were divided into S- 1 group（n=48） and SOX group（n=26）according to the chemotherapy from Jan 2010 to Dec 2013, the efficacy and safety were compared between the two groups. Results The response rate ,the median overall survival （OS） and the median progression-free survival （PFS） in the S-1 group were significantly shorter than those in the SOX group （27.1% vs 42.3% ,9.2 months vs 15.3 months,4.1 months vs 7.3 months,all P〈0.05）. The leukocytopenia, neutropenia, anorexia, nausea, vomitting, sensory neuropathy in the S-1 group were significantly higher than those in the SOX group （23.1% vs 4.2%,26.9% vs 6.3 %,26.9% vs 16.7 %,23.1% vs 4.2%,15.4 % vs 0.0%,15.4 % vs 0.0% ,all P〈O.05）. Conclusion Compared with S-1 ,SOX may improve OS and well tolerated for elderly patients with advanced gastric cancer.